NEW ORLEANS

新奥尔良

,

，

June 7, 2026

2026年6月7日

/PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ('Sciwind Biosciences'), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from a head-to-head study (SLIMMER-UP-SWITCH) evaluating ecnoglutide versus semaglutide was presented as a Late-Breaking abstract at the 86th Scientific Sessions of the American Diabetes Association (ADA) 2026.

/美通社/ -- 专注于发现和开发代谢疾病创新疗法的商业化阶段生物制药公司杭州赛科文德生物医药有限公司（“赛科文德”）今日宣布，评估艾可格鲁肽与司美格鲁肽的头对头研究（SLIMMER-UP-SWITCH）的关键数据以最新突破摘要的形式在美国糖尿病协会（ADA）2026年第86届科学年会上发表。

Interim analysis results showed that ecnoglutide, the world's first approved cAMP-biased .

中期分析结果显示，ecnoglutide 是全球首款获批的 cAMP 偏向性

GLP-1

胰高血糖素样肽-1

receptor agonist, demonstrated greater weight loss compared to semaglutide, with a 35% greater reduction in body weight, a 20% greater reduction in waist circumference at Week 20, and nearly twice as many patients achieving ≥10% body weight loss.

受体激动剂与司美格鲁肽相比，显示出更大的体重减轻效果，在第20周时体重减少幅度高出35%，腰围减少幅度高出20%，且达到≥10%体重减轻的患者人数几乎多出两倍。

Professor Linong Ji, Director of the Department of Endocrinology at Peking University People's Hospital, stated that this study provides the first direct clinical evidence validating the clinical advantages of the innovative cAMP-biased

北京大学人民医院内分泌科主任纪立农教授表示，这项研究提供了首个直接临床证据，验证了创新性cAMP偏向性

GLP-1

胰高血糖素样肽-1

receptor agonist mechanism. By optimizing

受体激动剂机制。通过优化

GLP-1

胰高血糖素样肽-1

receptor signal transduction, it delivers superior clinical benefits over traditional

受体信号转导，相较于传统方法，它提供了更优越的临床获益

GLP-1

GLP-1

receptor agonists, providing high-quality evidence-based medical evidence for the field of weight management.

受体激动剂，为体重管理领域提供高质量的循证医学证据。

Clear Weight Loss Advantage at Week 20: 35% Greater Mean Weight Reduction vs. Semaglutide, ≥10% Weight Loss Response Rate Nearly Twofold Higher

第20周显现出显著的减重优势：与司美格鲁肽相比，平均体重降幅高出35%，≥10%的体重减轻反应率接近其两倍

This study enrolled 163 adult patients with obesity (body mass index [BMI]≥30 kg/m²) across 17 research centers in China. Participants were randomized 1:1 to receive once-weekly subcutaneous injections of either ecnoglutide or semaglutide at the same maintenance dose of 2.4 mg¹.

本研究在中国17个研究中心纳入了163例成年肥胖患者（体重指数[BMI]≥30 kg/m²）。参与者按1:1的比例随机分配，每周一次皮下注射艾科格鲁肽或司美格鲁肽，维持剂量均为2.4 mg¹。

Study data showed that at week 20, the least-squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide group (P<0.0001). The proportion of participants achieving ≥5% weight loss was 99% in the ecnoglutide group versus 86% in the semaglutide group (P<0.01).

研究数据显示，在第20周，ecnoglutide组与semaglutide组自基线起体重变化的最小二乘均值百分比分别为-12.8%和-9.5%（P<0.0001）。实现≥5%体重减轻的参与者比例在ecnoglutide组为99%，而在semaglutide组为86%（P<0.01）。

The proportion achieving ≥10% weight loss was 74% in the ecnoglutide group versus 40% in the semaglutide group (P<0.001)..

在ecnoglutide组中，达到≥10%体重减轻的比例为74%，而在semaglutide组中为40%（P<0.001）。

Significant Circumference Benefits: 20% Greater Waist Circumference Reduction vs. Semaglutide

显著的围度获益：腰围缩减幅度较司美格鲁肽提高20%

In addition to potent weight loss, ecnoglutide also demonstrated remarkable advantages in improving body circumference. Study data showed that at week 20, the mean reduction in waist circumference from baseline was 10.5 cm in the ecnoglutide group and 8.7 cm in the semaglutide group (P<0.05), representing a 20% greater reduction for ecnoglutide.

除了显著的减重效果外，ecnoglutide 在改善身体围度方面也表现出显著优势。研究数据显示，在第 20 周时，ecnoglutide 组的腰围较基线平均减少 10.5 cm，semaglutide 组平均减少 8.7 cm（P<0.05），ecnoglutide 的降幅高出 20%。

Improvements in other circumference measures including arm circumference and neck circumference were also superior to those of semaglutide¹..

包括臂围和颈围在内的其他周径指标的改善也优于司美格鲁肽¹。

Professor Linong Ji noted: 'Central obesity, characterized by abdominal fat accumulation, not only affects body shape but is also a key risk factor for type 2 diabetes, metabolic syndrome and cardiovascular diseases. While effectively reducing body weight, ecnoglutide significantly improves central obesity and local fat accumulation, optimizing body shape while lowering the risk of related metabolic diseases.'.

纪立农教授指出：“中心性肥胖以腹部脂肪堆积为特征，不仅影响体型，还是2型糖尿病、代谢综合征和心血管疾病的关键风险因素。依科格鲁肽在有效减轻体重的同时，显著改善中心性肥胖和局部脂肪堆积，在优化体型的同时降低相关代谢性疾病的风险。”

Nobel Prize-Winning Research Translation: Biased Mechanism Achieves Balance Between Efficacy and Safety

诺贝尔奖获奖研究译介：偏向性机制实现疗效与安全性的平衡

Traditional

传统

GLP-1

胰高血糖素样肽-1

receptor agonists mostly adopt a 'full pathway activation' mode, which activates weight loss signaling pathways but also often activates pathways associated with gastrointestinal adverse events and receptor desensitization, making it difficult to balance potent weight loss and good tolerability.

受体激动剂大多采用“全通路激活”模式，该模式在激活减重信号通路的同时，也常常激活与胃肠道不良事件及受体脱敏相关的通路，因而难以在强效减重与良好耐受性之间取得平衡。

Based on Nobel Prize-winning research findings

基于诺贝尔奖获奖研究成果

3

3

, ecnoglutide further contributes the industry-wide challenge of balancing efficacy and tolerability in traditional weight loss therapies by optimizing

，ecnoglutide 通过优化，进一步助力解决传统减肥疗法中平衡疗效与耐受性的行业性挑战

GLP-1

胰高血糖素样肽-1

receptor signal transduction. Its safety profile was also reaffirmed in this head-to-head study. Consistent with previous SLIMMER study results, ecnoglutide demonstrated favorable gastrointestinal safety

受体信号转导。在这项头对头研究中，其安全性特征也得到了再次确认。与既往SLIMMER研究结果一致，ecnoglutide显示出良好的胃肠道安全性

1,2

1,2

.

。

Dr. Hai Pan, Founder and CEO of Sciwind Biosciences, stated: 'We are honored to present this major breakthrough at the ADA Scientific Sessions, the world's most influential academic conference in the global metabolic field. Better weight loss therapies do not come from simple stacking of targets, but from precise regulation of key biological mechanisms.

海潘博士，Sciwind Biosciences 的创始人兼首席执行官表示：“我们很荣幸在 ADA 科学会议上展示这一重大突破，这是全球代谢领域最具影响力的学术会议。更好的减肥疗法并非来自靶点的简单叠加，而是源于对关键生物机制的精准调控。”

The head-to-head study of ecnoglutide versus semaglutide provides direct clinical evidence for this innovative concept, marking an important milestone in the translation of biased agonist mechanisms from cutting-edge science to clinical application. From Nobel Prize-level basic research to patient-accessible clinical products, we will remain committed to scientific translation, turning more cutting-edge scientific achievements into tangible health benefits for patients worldwide.'.

艾可格鲁肽与司美格鲁肽的头对头研究为这一创新概念提供了直接的临床证据，标志着偏倚激动剂机制从前沿科学向临床应用转化的重要里程碑。从诺贝尔奖级别的基础研究到患者可及的临床产品，我们将始终致力于科学转化，将更多前沿科学成果转化为全球患者切实可享的健康福祉。

Jean-Christophe Pointeau, Global Senior Vice President and President of Pfizer China, stated: 'These new findings add to the clinical evidence that new generation biased

辉瑞全球高级副总裁兼中国区总裁让-克里斯托夫·庞蒂厄表示：“这些新发现为新一代偏向性

GLP-1

胰高血糖素样肽-1

therapies in weight management and metabolic treatment can offer patients enhanced efficacy, tolerability and safety. As the commercialization partner for ecnoglutide in China, Pfizer is proud to support the introduction of this therapy and help expand access, providing new options to help people in China manage weight in a healthy way.'.

在体重管理和代谢治疗方面，这些疗法可为患者提供更高的疗效、更好的耐受性和安全性。作为艾可格鲁肽在中国的商业化合作伙伴，辉瑞公司很荣幸支持该疗法的引进，并帮助扩大其可及性，为中国人群提供新的选择，以健康的方式管理体重。

About the SLIMMER-UP-SWITCH Head-to-Head Study¹

关于SLIMMER-UP-SWITCH头对头研究¹

SLIMMER-UP-SWITCH is a multicenter, randomized, open-label Phase 2 clinical trial conducted at 17 research centers in China, enrolling 163 adult patients with obesity (BMI ≥30 kg/m²). Participants were randomized 1:1 to receive once-weekly subcutaneous injections of ecnoglutide or semaglutide for a 60-week treatment period, with a pre-specified interim analysis conducted at Week 20.

SLIMMER-UP-SWITCH 是一项在中国17家研究中心开展的多中心、随机、开放标签的II期临床试验，共入组163名肥胖成年患者（BMI ≥30 kg/m²）。参与者按1:1的比例随机分配，接受每周一次皮下注射艾科格鲁肽或司美格鲁肽，治疗期为60周，并在第20周进行预先指定的中期分析。

The interim analysis data of this study has been selected as a Late Breaking abstract and presented as a poster at the 2026 ADA Scientific Sessions..

本研究的期中分析数据被选为“最新突破”摘要，并在2026年美国糖尿病协会（ADA）科学会议上以海报形式展示。

About the SLIMMER Study²

关于 SLIMMER 研究²

The SLIMMER study is a large-scale Phase 3 clinical trial that enrolled 664 Chinese adult subjects with overweight or obesity. In the SLIMMER study, ecnoglutide demonstrated clinically meaningful efficacy. After 48 weeks of treatment, subjects in the highest dose group (2.4 mg) achieved an average weight loss of 15.4%, with 92.8% of subjects losing more than 5% of their body weight.

SLIMMER研究是一项大型III期临床试验，共入组664名超重或肥胖的中国成年受试者。在SLIMMER研究中，ecnoglutide展现出具有临床意义的疗效。经过48周的治疗，最高剂量组（2.4 mg）受试者的平均体重减轻幅度达到15.4%，其中92.8%的受试者体重减轻超过5%。

The study also observed a significant reduction in waist circumference (average reduction of 12.8 cm), a 53.1% average reduction in liver fat content in subjects with baseline fatty liver disease, and significant improvements in multiple metabolic indicators including blood pressure, blood lipids and blood glucose; in addition, uric acid levels decreased by an average of 54.3 μmol/L.

该研究还观察到腰围显著减少（平均减少12.8厘米），基线患有脂肪肝的受试者肝脏脂肪含量平均减少53.1%，包括血压、血脂和血糖在内的多项代谢指标显著改善；此外，尿酸水平平均降低54.3 μmol/L。

In the study, the treatment discontinuation rate due to adverse events was 2%, and the discontinuation rate due to gastrointestinal adverse events was 0.6%..

在该研究中，因不良事件导致的治疗中止率为2%，因胃肠道不良事件导致的中止率为0.6%。

About Ecnoglutide

关于艾克诺格鲁肽

Ecnoglutide is a cAMP-biased

Ecnoglutide 是一种 cAMP 偏向性

GLP-1

GLP-1

receptor agonist developed by Sciwind Biosciences for obesity and related metabolic diseases. Pfizer has exclusive commercialization rights for Sciwind's injectible ecnoglutide product in Mainland China.

由Sciwind Biosciences开发的用于治疗肥胖及相关代谢疾病的受体激动剂。辉瑞公司拥有Sciwind旗下注射用ecnoglutide产品在中国大陆的独家商业化权利。

About Sciwind Biosciences

关于赛风生物科学

Sciwind Biosciences is a commercial-stage biopharmaceutical company, dedicated to addressing the unmet medical needs in the field of weight management and metabolic diseases. Sciwind has established a robust pipeline anchored by the lead asset, ecnoglutide (XW003). It has developed multiple proprietary technology platforms, including biased agonist discovery platform, long-acting and oral peptide delivery platforms, and has identified a series of drug candidates based on these core technology platforms.

Sciwind Biosciences 是一家处于商业化阶段的生物制药公司，致力于满足体重管理和代谢疾病领域未竟的医疗需求。Sciwind 以核心资产 ecnoglutide（XW003）为支柱，建立了强大的产品管线。公司已开发多个专有技术平台，包括偏向性激动剂发现平台、长效肽递送平台和口服肽递送平台，并基于这些核心技术平台筛选出一系列候选药物。

Sciwind has built an extensive pipeline targeting .

Sciwind已建立一条针对的广泛产品管线。

GLP-1

胰高血糖素样肽-1

and synergistic pathways, offering both injectable and oral treatment solutions to deliver sustainable and high-quality therapies for patients with metabolic diseases.

以及协同作用途径，提供注射和口服治疗解决方案，为代谢性疾病患者提供可持续且高质量的治疗。

For more information, please visit Sciwind Biosciences' official website:

如需更多信息，请访问赛风生物科学公司官方网站：

www.sciwind.com.cn

www.sciwind.com.cn

References

参考文献

2026 ADA poster 12-B. Study number SCW0502-1122

2026年美国糖尿病协会海报12-B。研究编号SCW0502-1122

Ji L, et al. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789

纪立农，等. 《柳叶刀·糖尿病与内分泌学》. 2025年9月；13(9):777-789

Mullard A. Nat Rev Drug Discov. 2023 May;22(5)347-348.

穆拉德 A. 《自然综述·药物发现》. 2023年5月；22(5):347-348.

SOURCE Sciwind Biosciences Co., Ltd.

来源：上海赛风生物科技有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示